The latest price target for Plus Therapeutics (NASDAQ:PSTV) was reported by HC Wainwright & Co. on November 15, 2024. The analyst firm set a price target for $8.00 expecting PSTV to rise to within 12 months (a possible 609.35% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Plus Therapeutics (NASDAQ:PSTV) was provided by HC Wainwright & Co., and Plus Therapeutics reiterated their buy rating.

There is no last upgrade for Plus Therapeutics

There is no last downgrade for Plus Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Plus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Plus Therapeutics was filed on November 15, 2024 so you should expect the next rating to be made available sometime around November 15, 2025.

While ratings are subjective and will change, the latest Plus Therapeutics (PSTV) rating was a reiterated with a price target of $8.00 to $8.00. The current price Plus Therapeutics (PSTV) is trading at is $1.13, which is out of the analyst’s predicted range.